Novo Nordisk is well-positioned for long-term growth despite recent price cuts on Wegovy, which could actually strengthen its competitive moat by pricing out compounders and lower-quality competitors while establishing it as the trusted standard in the obesity market. The company has multiple growth drivers including European expansion, promising pipeline candidates (UBT251, oral Wegovy, oral CagriSema), and the ability to generate stable recurring cash flows to fund innovation.